Resilience Biosciences Inc (RBI) is a clinical-stage biopharmaceutical company developing non-opioid, evidence-based, herbal and small-molecule therapeutics to address opioid withdrawal, withdrawal-associated pain, and cognitive deficits.
Inspired by nature, driven by science and innovation.
We leverage translational neuroscience, clinical research, herbal medicine, and modern chemistry to create innovative, science-driven solutions to critical unmet needs.
About Us
Who we serve and work with:
- People experiencing opioid withdrawal, associated pain, or cognitive deficits
- Clinicians and healthcare systems
- Researchers and partners
- Funders and public agencies
Company
Turning clinical and neurobiological insights into high-impact therapeutics. Learn More
Team
Expertise across drug development, neuroscience, psychiatry, and chemistry. Learn More
Research Pipelines
RBI is pursuing 3 synergistic research pipelines. Learn More
Publications
Papers in published in peer-reviewed journals. Learn More
About
Research
RBI-01
12-plant, non-opioid herbal formulation (approved supplement).
RBI-02
Novel T-type calcium channel antagonists.
RBI-03
Novel, nature-inspired dopamine modulator.
Research Pipelines
RBI is pursuing 3 synergistic research pipelines. Learn More
Publications
Papers in published in peer-reviewed journals. Learn More
About
Research
RBI-01
12-plant, non-opioid herbal formulation (approved supplement).
RBI-02
Novel T-type calcium channel antagonists.
RBI-03
Novel, nature-inspired dopamine modulator.